Healthcare and Medical
Healthcare and Medical
home | healthcare and medical | market report
The Cardiovascular Market Outlook to 2011 (Business Insights)
- Market: Healthcare and Medical
- Published Date: 01 Jan 2007
- Report Title: The Cardiovascular Market Outlook to 2011
- Table of Contents: View Table of Contents
- Report Type: Market Report
- Country: Global
- Number of Pages: 126
The Cardiovascular Market Outlook to 2011 is a new report providing analysis of the current and future market for cardiovascular drugs across all major indications. Forecasts are given based on new product launches, upcoming patent expiry dates, and ongoing clinical trials to enable you to predict changes in the dynamics of the global cardiovascular market.
This report offers insight into R&D trends in the cardiovascular market, including the discontinuation of key pipeline drugs such as Pfizer’s torcetrapib and atorvastatin, and the development of new drug classes including Novartis’ Rasilez (aliskiren), anticipated to be the first to market direct renin inhibitor.
Use this report to identify the leading cardiovascular companies to
2011 and discover the cardiovascular blockbusters of the future.
Key findings of the report...
• Anti-hypertensives have been the highest selling portion of the
cardiovascular market in 2005. Norvasc was the leading
anti-hypertensive drug in 2005, with sales of $5bn, an increase of 3.9%
from 2004.
• In 2006 the patents protecting Zocor and Pravachol expired, which
together with the anticipated patent expiry of Lipitor in 2010, will result
in a flood of generic statins onto the market, heavily
impacting sales of branded drugs.
• Two key anti-hypertensives are forecast to launch in 2007:
Novartis’ Rasilez (aliskiren) and Exforge (valsartan plus amlodipine).
Exforge gained FDA approval in December 2006 and is predicted to
generate high sales.
• Pfizer’s torcetrapib and atorvastatin was discontinued in late 2006
due to safety concerns. The discontinuation of torcetrapib will have an
impact on the other members of the CETP inhibitor pipeline drugs, in
particular Roche’s JTT-705.
• Pfizer is the leading global cardiovascular company, with sales of
nearly $20bn in 2005, representing 15.6% of the cardiovascular market.
• The largest growth seen in the cardiovascular market is from Amgen
at 17.4%, with sales in 2005 of $6.4bn.
Key questions answered in this report
• What were the key events in the global cardiovascular market in
2005-06?
• What are the drivers and resistors to growth for the key players in
the market?
• How has the failure of key pipeline products expected to impact the
global cardiovascular market?
• What strategies are the leading companies implementing to
maximize sales and boost market share?
• When will generic competition impact the leading cardiovascular
brands?
• Which new product launches are forecast to gain blockbuster status?
• What will the competitive landscape in hypertension, thrombosis,
dyslipidemia and arrhythmia look like in 2011?
Top five reasons to order your copy today
• Gain up-to-date competitive intelligence across the cardiovascular
area and understand the major issues affecting key pharmaceutical
marketers.
• Understand which cardiovascular indications have the greatest
potential for growth through the 6-year forecasts in anti-hypertensive,
anti-dyslipidemic, anti-thrombosis and cardiac therapy drug classes.
• Assess your potential competitive position to the leading
cardiovascular companies, through the report’s extensive pipeline
insight and profiles of upcoming launches.
• Examine factors impacting pipeline drugs, such as clinical trial results,
discontinued products and patient potentials.
• Identify the critical success factors for your company to succeed in
the cardiovascular market, through examination of winning growth
strategies used by the leading players.
This report offers insight into R&D trends in the cardiovascular market, including the discontinuation of key pipeline drugs such as Pfizer’s torcetrapib and atorvastatin, and the development of new drug classes including Novartis’ Rasilez (aliskiren), anticipated to be the first to market direct renin inhibitor.
Use this report to identify the leading cardiovascular companies to
2011 and discover the cardiovascular blockbusters of the future.
Key findings of the report...
• Anti-hypertensives have been the highest selling portion of the
cardiovascular market in 2005. Norvasc was the leading
anti-hypertensive drug in 2005, with sales of $5bn, an increase of 3.9%
from 2004.
• In 2006 the patents protecting Zocor and Pravachol expired, which
together with the anticipated patent expiry of Lipitor in 2010, will result
in a flood of generic statins onto the market, heavily
impacting sales of branded drugs.
• Two key anti-hypertensives are forecast to launch in 2007:
Novartis’ Rasilez (aliskiren) and Exforge (valsartan plus amlodipine).
Exforge gained FDA approval in December 2006 and is predicted to
generate high sales.
• Pfizer’s torcetrapib and atorvastatin was discontinued in late 2006
due to safety concerns. The discontinuation of torcetrapib will have an
impact on the other members of the CETP inhibitor pipeline drugs, in
particular Roche’s JTT-705.
• Pfizer is the leading global cardiovascular company, with sales of
nearly $20bn in 2005, representing 15.6% of the cardiovascular market.
• The largest growth seen in the cardiovascular market is from Amgen
at 17.4%, with sales in 2005 of $6.4bn.
Key questions answered in this report
• What were the key events in the global cardiovascular market in
2005-06?
• What are the drivers and resistors to growth for the key players in
the market?
• How has the failure of key pipeline products expected to impact the
global cardiovascular market?
• What strategies are the leading companies implementing to
maximize sales and boost market share?
• When will generic competition impact the leading cardiovascular
brands?
• Which new product launches are forecast to gain blockbuster status?
• What will the competitive landscape in hypertension, thrombosis,
dyslipidemia and arrhythmia look like in 2011?
Top five reasons to order your copy today
• Gain up-to-date competitive intelligence across the cardiovascular
area and understand the major issues affecting key pharmaceutical
marketers.
• Understand which cardiovascular indications have the greatest
potential for growth through the 6-year forecasts in anti-hypertensive,
anti-dyslipidemic, anti-thrombosis and cardiac therapy drug classes.
• Assess your potential competitive position to the leading
cardiovascular companies, through the report’s extensive pipeline
insight and profiles of upcoming launches.
• Examine factors impacting pipeline drugs, such as clinical trial results,
discontinued products and patient potentials.
• Identify the critical success factors for your company to succeed in
the cardiovascular market, through examination of winning growth
strategies used by the leading players.
Browse over 450,000 market research reports, company profile reports and company financials. Search by industry sector, or simply search market research reports or company profiles by keyword. Companiesandmarkets.com contains one of the world's largest collections of market research reports and company profiles from leading global market research report publishers and analysts. Global brands rely on companiesandmarkets.com for their strategic market research needs.
Purchase Information
There are various ways to purchase products from our site. Select the report title(s) you are interested in, and add it to your basket. At the Checkout page, you will be requested to submit your details. You will then have the option to pay via various methods: Debit Card, Credit Card, or by Invoice.
Companiesandmarkets.com accepts Visa, MasterCard, Diners, American Express, JCB and all the major credit cards. Companiesandmarkets.com uses RBSWorldpay.
Once you have purchased your report(s), you will receive a confirmation email. You will then either be able to download your report(s) immediately from your Customer Area in PDF format, or the report(s) will be emailed to you directly, depending on the agreement we have with the publisher. Orders that are deliverable via email which are taken outside of working hours will be delivered next business day.
Please note, if you purchase by invoice, you will receive your report(s) once payment has been received. If you have any questions about how to order, please Contact Us.
